Breaking: Deutsche Bank Reconfirms $23 Target Price per Share On Lannett (NYSE:LCI) Shares, Reconfirms Their Original “Hold” Rating

July 17, 2017 - By Marry Poplack

 Breaking: Deutsche Bank Reconfirms $23 Target Price per Share On Lannett (NYSE:LCI) Shares, Reconfirms Their Original

Investors sentiment decreased to 0.73 in 2016 Q4. Its down 0.63, from 1.36 in 2016Q3. It is negative, as 43 investors sold Lannett Company, Inc. shares while 46 reduced holdings. 20 funds opened positions while 45 raised stakes. 32.74 million shares or 14.44% more from 28.61 million shares in 2016Q3 were reported.

First Manhattan has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 685 shares. Envestnet Asset Mngmt has 11,037 shares. Northern Tru Corp has 0% invested in Lannett Company, Inc. (NYSE:LCI). Thompson Siegel And Walmsley Llc, a Virginia-based fund reported 901,729 shares. Advsr Asset Mgmt Inc stated it has 0.01% in Lannett Company, Inc. (NYSE:LCI). Moreover, Wells Fargo & Mn has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 84,075 shares. Comerica Comml Bank invested in 31,180 shares. Reilly Advsrs Lc reported 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Legal & General Pcl holds 50,063 shares. Moreover, Kennedy Management Inc has 0.03% invested in Lannett Company, Inc. (NYSE:LCI). Numeric Invsts Limited Liability Co reported 45,851 shares or 0.01% of all its holdings. Charlemagne Ltd holds 0.08% or 6,323 shares. Us Bancorp De stated it has 334 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 31,400 shares. Rhumbline Advisers owns 47,124 shares for 0% of their portfolio.

Since February 6, 2017, it had 1 buying transaction, and 0 sales for $200,000 activity. $200,000 worth of stock was bought by BEDROSIAN ARTHUR P on Monday, February 6.

Lannett (NYSE:LCI) Rating Reaffirmed

The firm has just set a target price of $23 on Lannett (NYSE:LCI) shares. This is 2.00 % from the previous stock close. In a research note revealed to investors and clients on Monday, 17 July, Deutsche Bank restate their “Hold” rating on shares of LCI.

Investors sentiment decreased to 0.73 in 2016 Q4. Its down 0.63, from 1.36 in 2016Q3. It is negative, as 43 investors sold Lannett Company, Inc. shares while 46 reduced holdings. 20 funds opened positions while 45 raised stakes. 32.74 million shares or 14.44% more from 28.61 million shares in 2016Q3 were reported.

First Manhattan has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 685 shares. Envestnet Asset Mngmt has 11,037 shares. Northern Tru Corp has 0% invested in Lannett Company, Inc. (NYSE:LCI). Thompson Siegel And Walmsley Llc, a Virginia-based fund reported 901,729 shares. Advsr Asset Mgmt Inc stated it has 0.01% in Lannett Company, Inc. (NYSE:LCI). Moreover, Wells Fargo & Mn has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 84,075 shares. Comerica Comml Bank invested in 31,180 shares. Reilly Advsrs Lc reported 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Legal & General Pcl holds 50,063 shares. Moreover, Kennedy Management Inc has 0.03% invested in Lannett Company, Inc. (NYSE:LCI). Numeric Invsts Limited Liability Co reported 45,851 shares or 0.01% of all its holdings. Charlemagne Ltd holds 0.08% or 6,323 shares. Us Bancorp De stated it has 334 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 31,400 shares. Rhumbline Advisers owns 47,124 shares for 0% of their portfolio.

Since February 6, 2017, it had 1 buying transaction, and 0 sales for $200,000 activity. $200,000 worth of stock was bought by BEDROSIAN ARTHUR P on Monday, February 6.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Among 9 analysts covering Lannett (NYSE:LCI), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Lannett has $70 highest and $3 lowest target. $42.07’s average target is 86.56% above currents $22.55 stock price. Lannett had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, June 29 by Deutsche Bank. The company was maintained on Thursday, March 24 by Roth Capital. Zacks upgraded it to “Strong-Buy” rating and $63 target in Monday, September 7 report. The stock of Lannett Company, Inc. (NYSE:LCI) has “Buy” rating given on Thursday, September 3 by Roth Capital. The rating was initiated by Susquehanna on Tuesday, July 21 with “Positive”. The rating was maintained by Roth Capital with “Buy” on Friday, March 11. The stock has “Buy” rating by Craig Hallum on Thursday, February 4. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Buy” rating by Craig Hallum on Thursday, August 27. As per Thursday, September 3, the company rating was maintained by TH Capital. The stock has “Hold” rating by Craig Hallum on Thursday, November 5.

About 358,730 shares traded. Lannett Company, Inc. (NYSE:LCI) has declined 2.16% since July 17, 2016 and is downtrending. It has underperformed by 18.86% the S&P500.

Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on August, 22. They expect $0.86 EPS, up 17.81 % or $0.13 from last year’s $0.73 per share. LCI’s profit will be $34.12 million for 6.56 P/E if the $0.86 EPS becomes a reality. After $0.77 actual EPS reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts 11.69 % EPS growth.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The company has market cap of $894.73 million. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. It currently has negative earnings. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: Prnewswire.com which released: “Lannett Appoints Samuel H. Israel As General Counsel” on July 17, 2017, also Seekingalpha.com with their article: “Lannett: Bullish Possibilities Despite Massive Short Interest” published on June 27, 2017, Prnewswire.com published: “Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone …” on June 26, 2017. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: Prnewswire.com and their article: “Lannett Receives Approval For Niacin Extended-Release Tablets USP, 500 Mg And …” published on June 19, 2017 as well as Prnewswire.com‘s news article titled: “Lannett Names Patrick G. LePore To Board of Directors” with publication date: June 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com